Phio Pharmaceuticals Corp. - שווי חברה להכנסות PHIO

Phio Pharmaceuticals is developing an immuno-oncology ecosystem, establishing an exclusive patent barrier through unique protocols. The price-to-sales multiple reflects the market reaction to these achievements, where 0.00 determines the latest valuation metric. Business scalability is based on the creation of high-margin RNA molecules, while the scientific pipeline is currently focused on clinical trials for solid tumor therapies.
Phio Pharmaceuticals Corp - פילוחים אנליטיים ומדדי מפתח (PHIO)

This multiple determines the market value of the business minus net debt relative to sales volume, revealing the efficiency of asset monetization without the influence of debt load. By analyzing the enterprise value-to-revenue ratio of Phio Pharmaceuticals (PHIO), an investor can assess the resilience of this small-cap biotech in the face of patent dominance by RNA interference behemoths, where inflated valuations often mask risks of technological stagnation.